BioSpace News Archive

KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”) today announced that the Company will report second quarter 2023 financial results on Wednesday, August 9, 2023.

Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on August 10, 2023, at 4:30 PM Eastern Time to discuss results for its second quarter ended June 30, 2023.

Cidara Therapeutics, Inc. (Nasdaq: CDTX) today announced an update on REZZAYO™ (rezafungin for injection) which was approved by the U.S. Food and Drug Administration (FDA) earlier this year.

The application for the start of the clinical phase I/IIa study of the radionuclide therapy program Tumorad with the candidate drug 177Lu-SN201 in cancer patients, Tumorad-01, was submitted to an Australian ethics committee.

Invectys, Inc., a clinical-stage immuno-oncology company focused on developing novel therapies for advanced cancers, is pleased to announce the U.S. Food and Drug Administration has granted Fast Track designation to its revolutionary product, IVS-3001.

Opteev Technologies, Inc., a pioneering technology company at the forefront of diagnostics, has filed a patent for a revolutionary multiplex biochip for respiratory infection diagnostics.

ImmunoGen, Inc. announced that Anna Berkenblit, MD, Senior Vice President and Chief Medical Officer, is stepping down from her position with the Company to take a well-deserved professional hiatus prior to pursuing new opportunities outside of ImmunoGen.

ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, reviewed recent progress in the business and reported financial results for the quarter ended June 30, 2023.

Labcorp today announced it will host an Investor Day on Thursday, September 14, 2023 , in New York City , beginning at 1:00 p.m. ET and is expected to conclude by approximately 4:00 p.m. ET.

Eagle Pharmaceuticals, Inc. announced that it has raised its Adjusted non-GAAP earnings per share and Adjusted non-GAAP EBITDA guidance for the 2023 fiscal year.